1. Introduction
Alzheimer's disease (AD) is a progressive neurodegenerative disease that causes debilitating dementia. For yet unknown reason, AD often leads also to emotional instability. Neuropathologically, AD brains are characterized by the presence of extracellular fibrillar amyloid beta peptide (Aβ) in amyloid plaques, intraneuronal neurofibrillary tangles consisting of aggregated hyperphosphorylated tau, and elevated brain levels of soluble Aβ oligomers. Plaques and neurofibrillary tangles are observed mostly in the cerebral cortex, but subcortical regions such as nucleus basalis, thalamus, locus coeruleus and raphe nuclei are also affected (Price et al., 1991). The amygdala is another important subcortical region that is severely and consistently affected by pathology in AD. This chapter will discuss the neuropathological features of the amygdala affected by AD and the resulting psychological, emotional and cognitive disturbances in AD patients and in model mice of this disease.
2. Emotional disturbances in AD patients
The amygdala is part of the limbic system that plays a major role in the processing and memorizing of emotional reactions (Schafe et al., 2005). The involvement of the amygdala in emotion has been evidenced in monkeys by the overwhelming loss of normal social and affective behavior resulting from bilateral damage to this structure (Izquierdo et al., 2005; Izquierdo and Murray, 2007). The amygdala is affected early in AD and results by neuropsychiatric symptoms leading to functional deficits that greatly contribute to the disability associated with this disease. Due to the early damage to the amygdala, neuropsychiatric symptoms are very common in mild stages of AD. Eventually, approximately 80% of the patients with AD present neuropsychiatric symptoms, such as hallucinations, delusions, paranoia, anxiety, agitation, and affective disturbances during the course of their illness (Mega et al., 1996; Lyketsos et al., 2002). Other symptoms such as dysphoria, irritability, disinhibition and apathy are also common (Kaufer et al., 1998). In addition to these symptoms, AD patients frequently show personality changes that affect their activities of daily living and the interaction with their caregivers. Personality changes may appear in any phase of dementia but often precede other early clinical manifestations of the disease, such as cognitive impairment and mood changes. These changes may therefore help in the clinical diagnosis of AD at early stages (Robins Wahlin and Byrne, 2011). Interestingly, personality changes and some of the neuropsychiatric symptoms (agitation, dysphoria and apathy) are better correlated with the severity of cognitive, functional and behavioral signs than with the patient’s age, gender, education or disease duration (Mega et al., 1996; Talassi et al., 2007). Thus, personality changes and neuropsychiatric symptoms may reflect the impact of progressive brain damage in AD (Robins Wahlin and Byrne, 2011).
3. Emotional memory in AD
Emotional memory is a form of episodic memory defined as memory of arousing emotional events. These memories are sometimes referred to as "flashbulb" memories (Hamann et al., 2000). Results from studies in animals and humans have strongly implicated the amygdala in this memory type (LaBar, 2003; Brierley et al., 2004; Richter-Levin, 2004). While it is recognized that normal people better remember events associated with an emotional component, there is a controversy regarding the strength of emotional memory in AD patients (Satler et al., 2007; Schultz et al., 2009; Huijbers et al., 2011; Nashiro and Mather, 2011; Sundstrom, 2011). Since the amygdala is one of the structures damaged in early stages of the AD pathology, it has been hypothesized that emotional memory should be impaired in AD patients. Indeed, data have shown that unlike healthy individuals, AD patients do not show memory enhancement for emotional events (enhanced memory for emotional compared to neutral stimuli) in spite of normal emotional reactions (Hamann et al., 2000). Notably, the degree of emotional memory impairment has positively been correlated with the extent of the amygdaloid atrophy (Mori et al., 1999a, b; Fleming et al., 2003).
4. Pathology of the amygdala in AD patients
While normal aging primarily affects the prefrontal cortex but relatively spares limbic regions, AD mainly affects limbic regions. The amygdala of AD patients shows a considerable shrinkage, distortion and loss of neurons, and widespread gliosis (Vereecken et al.; Herzog and Kemper, 1980; Cuenod et al., 1993). The amygdaloid atrophy in AD is the result of neuronal death (especially in the magnocellular basolateral amygdalar nuclei group) and loss of dendrites and axons. The accumulation of intraneuronal neurofibrillary tangles, Lewy bodies and extracellular Amyloid β peptide (Aβ) deposits in plaques also contribute significantly to the atrophy. Detailed pathological examination of the amygdala of AD patients reveals that many neurofibrillary tangles and Aβ plaques are located in the accessory basal and cortical nuclei and in the cortical transition area, whereas the mediobasal nucleus is less affected (Kromer Vogt et al., 1990). The medial, lateral, laterobasal and central nuclei are relatively free of neurofibrillary tangles and Aβ plaques (Kromer Vogt et al., 1990). Interestingly, it has been observed that the morphological deformation of the amygdala in AD patients is associated with intrinsic damage to its subnuclei and their reciprocal connectivity with other brain areas. Specifically, it has been reported that amygdaloid nuclei receiving input from and giving rise to hippocampal projections are consistently affected by neuropathological alterations in AD. In contrast, amygdaloid nuclei which receive strong cholinergic input from nucleus basalis of Meynert (e.g. laterobasal nucleus) are less affected (Kromer Vogt et al., 1990). To conclude, histological analysis of the amygdala of AD patients allows a thorough examination of this region thus rendering possible to detect nucleus-specific pathologies. Nevertheless, the major limitation of post-mortem analysis is that it is typically performed on brains taken from patients at late stages of the disease. Thus, information is lacking regarding neuropathological alterations in early stages of AD.
5. Imaging of the amygdala in vivo
Whereas histological procedures are used to investigate the anatomical complexity of the amygdala in brains from AD patients, a standard magnetic resonance imaging (MRI) technique can only detect few internal details and similar resolution cannot be obtained. The discovery that neuronal loss is a cause of amygdaloid atrophy provided the basis for later studies correlating amygdaloid volumetry, as measured with MRI, with the cognitive status of individual AD patients. Indeed, MRI-based volumetry is now regularly used as a research tool to explore the relationship between amygdaloid volume and the onset and progression of AD (de Leon et al., 1996; Mori et al., 1999a; Vasconcelos et al., 2011). While in the past the use of MRI was limited to clinical studies, the recent rise in MRI accessibility allowed its utilization for non-clinical studies aimed at investigating the involvement of the amygdala in emotion, memory processes and personality (Mori et al., 1999a). The main disadvantage of MRI-based amygdaloid volumetry consists in the difficulty to precisely and reliably delineate the contours of the amygdala
Numerous studies measuring the amygdaloid volume (normalized to intracranial volume) in AD patients at different clinical stages and in healthy age-matched controls showed a correlation of this factor with the neuropsychological performance of each patient. These studies have consistently demonstrated a decrease in amygdaloid volume in AD patients when compared to healthy controls (Horinek et al., 2007; Beacher et al., 2009; Cherubini et al., 2010; Lehmann et al., 2010; Vasconcelos Lde et al., 2011). Importantly, atrophy of the amygdala was found even in preclinical stages of the disease (Fox et al., 1996; Heun et al., 1997; Golebiowski et al., 1999). In fact, in the very early stages of AD, amygdaloid volume reductions were at least as large as hippocampal volume reductions although at this stage some overlap does exist between patients and healthy controls. Still, the volume of the amygdala has been suggested to be an independent variable in predicting conversion from mild cognitive impairment to AD (Liu et al., 2010).
6. The use of AD mice model to study the Aβ-dependent changes in the amygdala
In modern AD research, transgenic mice bearing infrequent mutations leading to familial forms of AD are being used to characterize in details the physiological, morphological and behavioral consequences of AD neuropathology in order to understand the anatomical and synaptic basis of dementia (Selkoe, 1996). These mutations include mutations in amyloid precursor protein (APP), the precursor of the Aβ peptide, or in presenilin (PS) 1 or 2, the catalytic subunit of the gamma secretase complex, which cleaves APP to form Aβ. Transgenic AD mice model represents an important tool to examine the consequences of
In a recent study, transgenic mice expressing a chimeric mouse/human amyloid precursor protein (Mo/HuAPP695swe) and a mutant human presenilin 1 (PS1-dE9) (APP/PS1, Borchelt et al., 1997) were used to study the morphological basis for amygdala-dependent cognitive impairment (Knafo et al., 2009). In this study, the authors first showed a clear impairment of auditory fear conditioning in APP/PS1 mice, a learning task that depends on the lateral nucleus of the amygdala (LA) (Knafo et al., 2009). Importantly, this cognitive deficit did not result from changes in anxiety or sensitivity to shock. Then, the authors used intracellular injection of Alexa594 into projection neurons in the LA, combined with thioflavin-S plaque staining (Fig. 2) and three-dimensional reconstructions of the dendritic trees and spines. The results of this study show that in APP/PS1 mice the morphology of projection neurons in the amygdala is modified, as reflected by changes in dendritic complexity, and that there is a
significant decrease in number of large spines on these neurons (Knafo et al., 2009). The authors emphasized the finding that the morphological alteration in dendrites and spines occur mainly in plaque-free areas that occupy most of the neuropil. Thus, as spines are main postsynaptic elements of excitatory synapses in the brain (Gray, 1959) and are fundamental in memory, learning and cognition (Lamprecht and LeDoux, 2004) the authors suggested that these changes, rather than changes detected within plaques contribute to the cognitive impairment seen in APP/PS1 mice.
To summarize, amygdala is significantly and consistently affected by Aβ both in patients with AD and in mouse models of this disease. Therefore, this region is a central participant in the pathology of AD (Unger et al., 1991) and its damage may be the structural substrate to the frequent emotional, psychological, and memory disturbances seen in this devastating disorder.
References
- 1.
MacAvoy MG, Varma P, Bronen RA, van Dyck CH (Basso M Yang J Warren L 2006 Volumetry of amygdala and hippocampus and memory performance in Alzheimer’s disease 146 251 261 - 2.
Beacher F Daly E Simmons A Prasher V Morris R Robinson C Lovestone S Murphy K Murphy D. G 2009 Alzheimer’s disease and Down’s syndrome: an in vivo MRI study. Psychological medicine39 675 684 - 3.
Borchelt D. R Ratovitski T Van Lare J Lee M. K Gonzales V Jenkins N. A Copeland N. G Price D. L Sisodia S. S 1997 Accelerated amyloid deposition in the brains of transgenic mice coexpressing mutant presenilin 1 and amyloid precursor proteins. 19 939 945 - 4.
Brierley B Medford N Shaw P David A. S 2004 Emotional memory and perception in temporal lobectomy patients with amygdala damage Journal of neurology, neurosurgery, and psychiatry75 593 599 - 5.
Di Paola M, Di Iulio F, Hagberg GE, Sancesario G, Gianni W, Bossu P, Caltagirone C, Sabatini U, Spalletta G (Cherubini A Peran P Spoletini I 2010 Combined volumetry and DTI in subcortical structures of mild cognitive impairment and Alzheimer’s disease patients. J Alzheimers Dis19 1273 1282 - 6.
Convit A Mchugh P Wolf O. T De Leon M. J Bobinski M De Santi S Roche A Tsui W 1999 MRI volume of the amygdala: a reliable method allowing separation from the hippocampal formation. Psychiatry Res90 113 123 - 7.
Cuenod C-A Denys A Michot J-L Jehenson P Forette F Kaplan D Syrota A Boller F 1993 Amygdala Atrophy in Alzheimer’s Disease: An In Vivo Magnetic Resonance Imaging Study. In,941 945 - 8.
De Leon M. J Convit A George A. E Golomb J De Santi S Tarshish C Rusinek H Bobinski M Ince C Miller D Wisniewski H 1996 In vivo structural studies of the hippocampus in normal aging and in incipient Alzheimer’s disease. 777 1 13 - 9.
Fleming K Kim S. H Doo M Maguire G Potkin S. G 2003 Memory for emotional stimuli in patients with Alzheimer’s disease Am J Alzheimers Dis Other Demen18 340 342 - 10.
Fox N. C Warrington E. K Freeborough P. A Hartikainen P Kennedy A. M Stevens J. M Rossor M. N 1996 Presymptomatic hippocampal atrophy in Alzheimer’s disease. A longitudinal MRI study. Brain 119 ( Pt 6):2001 EOF 7 EOF - 11.
Games D et al 1995 Alzheimer-type neuropathology in transgenic mice overexpressing n.717F beta]-amyloid precursor protei523 EOF 7 EOF - 12.
Golebiowski M Barcikowska M Pfeffer A 1999 Magnetic resonance imaging-based hippocampal volumetry in patients with dementia of the Alzheimer type Dement Geriatr Cogn Disord10 284 288 - 13.
Gray E. G 1959 Electron microscopy of synaptic contacts on dendrite spines of the cerebral cortex. 183 1592 1593 - 14.
Hamann S. B Monarch E. S Goldstein F. C 2000 Memory enhancement for emotional stimuli is impaired in early Alzheimer’s disease. 14 82 92 - 15.
Herholz K Weisenbach S Zandorf G Lenz O Schröder H Bauer B Kalbe E Heiss W. D 2004 In vivo study of acetylcholine esterase in basal forebrain, amygdala, and cortex in mild to moderate Alzheimer disease. 21 136 143 - 16.
Herzog A. G Kemper T. L 1980 Amygdaloid Changes in Aging and Dementia. In,625 629 - 17.
Heun R Mazanek M Atzor K. R Tintera J Gawehn J Burkart M Gansicke M Falkai P Stoeter P 1997 Amygdala-hippocampal atrophy and memory performance in dementia of Alzheimer type. Dement Geriatr Cogn Disord8 329 336 - 18.
Horinek D Varjassyova A Hort J 2007 Magnetic resonance analysis of amygdalar volume in Alzheimer’s disease. 20 273 277 - 19.
Olde Rikkert MG, Kessels RP (Huijbers M. J Bergmann H. C 2011 Memory for emotional pictures in patients with Alzheimer’s dementia: comparing picture-location binding and subsequent recognition Journal of aging research 2011:409364. - 20.
Izquierdo A Murray E. A 2007 Selective Bilateral Amygdala Lesions in Rhesus Monkeys Fail to Disrupt Object Reversal Learning. The Journal of Neuroscience27 1054 1062 - 21.
Izquierdo A Suda R. K Murray E. A 2005 Comparison of the Effects of Bilateral Orbital Prefrontal Cortex Lesions and Amygdala Lesions on Emotional Responses in Rhesus Monkeys. The Journal of Neuroscience25 8534 8542 - 22.
MacMillan A, Ketchel P, DeKosky ST (Kaufer D. I Cummings J. L Christine D Bray T Castellon S Masterman D 1998 Assessing the impact of neuropsychiatric symptoms in Alzheimer’s disease: the Neuropsychiatric Inventory Caregiver Distress Scale. 46 210 215 - 23.
Kawachi T Ishii K Sakamoto S Sasaki M Mori T Yamashita F Matsuda H Mori E 2006 Comparison of the diagnostic performance of FDG-PET and VBM-MRI in very mild Alzheimer’s disease 33 801 809 - 24.
Knafo S Venero C Merino-serrais P Fernaud-espinosa I Gonzalez-soriano J Ferrer I Santpere G Defelipe J 2009 Morphological alterations to neurons of the amygdala and impaired fear conditioning in a transgenic mouse model of Alzheimer’s diseas e. The Journal of pathology219 41 51 - 25.
Kohler C. G Anselmo-gallagher G Bilker W Karlawish J Gur R. E Clark C. M 2005 Emotion-Discrimination Deficits in Mild Alzheimer Disease American Journal of Geriatric Psych13 926 933 - 26.
Kromer Vogt LJ Hyman BT, Van Hoesen GW, Damasio AR (1990 Pathological alterations in the amygdala in Alzheimer’s disease. 37 377 385 - 27.
LaBar KS ( 2003 Emotional memory functions of the human amygdala3 363 364 - 28.
LeDoux J (Lamprecht R 2004 Structural plasticity and memory. 5 45 54 - 29.
Lehmann M Douiri A Kim L. G Modat M Chan D Ourselin S Barnes J Fox N. C 2010 Atrophy patterns in Alzheimer’s disease and semantic dementia: a comparison of FreeSurfer and manual volumetric measurements 49 2264 2274 - 30.
Liu Y Paajanen T Zhang Y Westman E Wahlund L. O Simmons A Tunnard C Sobow T Mecocci P Tsolaki M Vellas B Muehlboeck S Evans A Spenger C Lovestone S Soininen H 2010 Analysis of regional MRI volumes and thicknesses as predictors of conversion from mild cognitive impairment to Alzheimer’s disease. Neurobiology of aging31 1375 1385 - 31.
Lyketsos C. G Lopez O Jones B Fitzpatrick A. L Breitner J Dekosky S 2002 Prevalence of neuropsychiatric symptoms in dementia and mild cognitive impairment: results from the cardiovascular health study. Jama288 1475 1483 - 32.
Mega M. S Cummings J. L Fiorello T Gornbein J 1996 The spectrum of behavioral changes in Alzheimer’s disease. 46 130 135 - 33.
Merino-serrais P Knafo S Alonso-nanclares L Fernaud-espinosa I Defelipe J 2011 Layer-specific alterations to CA1 dendritic spines in a mouse model of Alzheimer’s disease 21 1037 1044 - 34.
Mesulam M 2004 The Cholinergic Lesion of Alzheimer’s Disease: Pivotal Factor or Side Show? Learning & Memory11 43 49 - 35.
Mori E Ikeda M Hirono N Kitagaki H Imamura T Shimomura T 1999a Amygdalar volume and emotional memory in Alzheimer’s disease. Am J Psychiatry156 216 222 - 36.
Mori E Ikeda M Hirono N Kitagaki H Imamura T Shimomura T 1999b Amygdalar volume and emotional memory in Alzheimer’s disease. 156 216 222 - 37.
Nashiro K Mather M 2011 Effects of emotional arousal on memory binding in normal aging and Alzheimer’s disease The124 301 312 - 38.
Perry E. K Blessed G Tomlinson B. E Perry R. H Crow T. J Cross A. J Dockray G. J Dimaline R Arregui A 1981 Neurochemical activities in human temporal lobe related to aging and Alzheimer-type changes. Neurobiology of aging2 251 256 - 39.
Price J. L Davis P. B Morris J. C White D. L 1991 The distribution of tangles, plaques and related immunohistochemical markers in healthy aging and Alzheimer’s disease. 12 295 312 - 40.
Richter-levin G 2004 The amygdala, the hippocampus, and emotional modulation of memory. The Neuroscientist : a review journal bringing neurobiology, neurology and psychiatry10 31 39 - 41.
Robins Wahlin TB Byrne GJ (2011 Personality changes in Alzheimer’s disease: a systematic review. Int J Geriatr Psychiatry26 1019 1029 - 42.
Satler C Garrido L. M Sarmiento E. P Leme S Conde C Tomaz C 2007 Emotional arousal enhances declarative memory in patients with Alzheimer’s disease. 116 355 360 - 43.
LeDoux JE (Schafe G. E Doyere V 2005 Tracking the fear engram: the lateral amygdala is an essential locus of fear memory storage. J Neurosci25 10010 10014 - 44.
Schultz R. R De Castro C. C Bertolucci P. H 2009 Memory with emotional content, brain amygdala and Alzheimer’s disease. Acta neurologica Scandinavica120 101 110 - 45.
Selkoe D. J 1996 Amyloid beta-protein andthe genetics of Alzheimer’s dis ease. The Journal of biological chemistry271 18295 18298 - 46.
Selkoe D. J 2002 Alzheimer’s disease is a synaptic failure. NY298 789 791 - 47.
Shinotoh H Fukushi K Nagatsuka S Tanaka N Aotsuka A Ota T Namba H Tanada S Irie T 2003 The Amygdala and Alzheimer’s Disease. Annals of the New York Academy of Sciences985 411 419 - 48.
Solano-castiella E Schäfer A Reimer E Türke E Pröger T Lohmann G Trampel R Turner R 2011 Parcellation of human amygdala in vivo using ultra high field structural MRI. Neuroimage58 741 748 - 49.
Spires T. L Hyman B. T 2005 Transgenic models of Alzheimer’s disease: Learning from animals. NeuroRx2 423 437 - 50.
Spires-jones T Knafo S 2012 Spines, Plasticity, and Cognition in Alzheimer’s Model Mice. Neural Plasticity 2012. - 51.
Sundstrom M 2011 Modeling recall memory for emotional objects in Alzheimer’s disease. Neuropsychology, development, and cognition Section B, Aging, and cognition18 396 413 - 52.
Talassi E Cipriani G Bianchetti A Trabucchi M 2007 Personality changes in Alzheimer’s disease. Aging Ment Health11 526 531 - 53.
Terry R. D 2000 Cell Death or Synaptic Loss in Alzheimer Disease. Journal of Neuropathology & Experimental Neurology59 1118 1119 - 54.
Terry R. D Masliah E Salmon D. P Butters N Deteresa R Hill R Hansen L. A Katzman R 1991 Physical basis of cognitive alterations in alzheimer’s disease: Synapse loss is the major correlate of cognitive impairment. 30 572 580 - 55.
Unger J. W Lapham L. W Mcneill T. H Eskin T. A Hamill R. W 1991 The amygdala in Alzheimer’s disease: neuropathology and Alz 50 immunoreactivity. 12 389 399 - 56.
Vasconcelos Lde G Jackowski AP, Oliveira MO, Flor YM, Bueno OF, Brucki SM (2011 Voxel-based morphometry findings in Alzheimer’s disease: neuropsychiatric symptoms and disability correlations- preliminary results. Clinics (Sao Paulo)66 1045 1050 - 57.
Vasconcelos LdG Jackowski AP, Oliveira MOd, Flor YMR, Bueno OFA, Brucki SMD (2011 Voxel-based morphometry findings in Alzheimer’s disease: neuropsychiatric symptoms and disability correlations- preliminary results. Clinics66 1045 1050 - 58.
Vereecken THLG Vogels OJM, Nieuwenhuys R Neuron loss and shrinkage in the amygdala in Alzheimer’s disease. Neurobiology of aging15 45 54 - 59.
Wright C. I Dickerson B. C Feczko E Negeira A Williams D 2007 A Functional Magnetic Resonance Imaging Study of Amygdala Responses to Human Faces in Aging and Mild Alzheimer’s Disease 62 1388 1395